Clinical Trial Update: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response [Phase 2]

View source ↗

Summary

Phase 2 trial update suggests supraphysiologic testosterone priming may extend the response to darolutamide in metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Nubeqa (darolutamide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING